CTOs on the Move

Kronos Bio

www.kronosbio.com

 
Kronos Bio is clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting dysregulated transcription. Our proprietary product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks (TRNs) through which they drive oncogenic activity.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.kronosbio.com
  • 1300 So. El Camino Real Suite 300
    San Mateo, CA USA 94402
  • Phone: n/a

Executives

Name Title Contact Details

Funding

Kronos Bio raised $18M on 05/23/2018
Kronos Bio raised $155M on 08/25/2020

Similar Companies

Applied Proteomics

Applied Proteomics Inc. is advancing the application of proteomics to the development of diagnostics, companion diagnostics, and personalized medicine applications to power better medical decisions and care. API has developed a proteomics platform solution to make protein-based biomarker discovery possible as a replicable, industrial application ready to be applied to health diagnostic problems.

BioAssay Works

BioAssay Works is a Ijamsville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Elevai Labs

ELEVAI LABS, INC. is a biotechnology company developing cutting-edge regenerative skincare applications. The company solves the unmet needs in the regenerative aesthetics space through a combination of cutting-edge science and next-generation consumer applications. Elevai Labs develops state-of-the-art topic anesthetic and pharmaceutical-grade skin care for the physician-dispensed market, with a focus on leveraging stem cell exosome technology.

Inform Genomics

Inform Genomics, Inc, is a privately held company that utilizes a proprietary technology platform to discover and develop genomic-based, precision medicine products that are designed to predict, with a high degree of accuracy, clinically important outcomes that assist physicians and their patients in making individualized medical decisions. Its lead development program is in oncology supportive care, with two major products currently in development--OnPART™ and HSCT/Mucositis™--designed not only to predict a patient's risk for developing common chemotherapy-related side effects, but also to assess a patient's willingness to tolerate those side effects. The Company's novel, IP-protected technology platform capitalizes on big data storage/memory and sophisticated cloud computing technologies. It consists of proprietary Bayesian networks and other advanced bioinformatic analytics combined with validated patient assessment tools. The Company's analytics discover interactions of genes and single nucleotide polymorphisms (SNPs) that can predict clinical outcomes. Inform Genomics' goal is to be a trusted partner to health care practitioners so that they, together with their patients, can make optimal health care choices based on an individual patient's needs and values.

Adarza BioSystems Inc

Adarza BioSystems, Inc. manufactures a label-free platform technology that enables the simultaneous detection of hundreds of analytes in a single drop of fluid.